The CEO of Turing Pharmaceuticals is defending his decision to raise the price of the life-saving drug Daraprim from $13.50 to $750 a tablet. Outrage over his decision has spread to the campaign trial and triggered instability on Wall Street. New York Times Reporter Andrew Pollack and Infectious Disease Specialist, Dr. Frank Esper join NewsNation.Sept. 22, 2015
UP NEXT
Doris Kearns Goodwin on watching JFK grow as a candidate and leader
08:48
'I will not have any jurors intimidated': Judge issues warning during trial
12:39
Doris Kearns Goodwin re-lived the 60s with her husband for 'An Unfinished Love Story'
07:51
A call for people to take control of our democracy: Eddie Glaude on his new book
08:06
What happened in day one of hush money trial and what to expect from day two
09:00
Doris Kearns Goodwin: We're moving backward in time and not forward